Antirheumatic drugs in pregnancy and lactation

Baillieres Clin Rheumatol. 1990 Apr;4(1):157-71. doi: 10.1016/s0950-3579(05)80249-3.


The natural inclination of patients with rheumatic diseases wishing to become pregnant or to breast feed will be to take as few medications as possible. The guidelines outlined above can be used to balance the risk of drug effect on the fetus or neonate with the risk of inducing a flare in disease activity by stopping the drug. Although there are situations where no information on drug behaviour during pregnancy or lactation exists, some guidelines can be developed from a knowledge of the drug's inherent metabolism. In the majority of the rheumatic diseases, disease activity can be reduced to a minimum using the smallest possible dose of drugs known to be safe in pregnancy and lactation, thus providing minimum risk to mother, fetus and neonate.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use*
  • Breast Feeding*
  • Female
  • Fetus / drug effects
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Complications / metabolism
  • Rheumatic Diseases / drug therapy*
  • Rheumatic Diseases / metabolism


  • Anti-Inflammatory Agents